Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Researchers develop model for early prediction of cancer patients' response to immunotherapy

Researchers have developed a model that could predict early on in treatment whether cancer patients will respond to immunotherapy, according to a report published today in eLife.

9 Nov 2021

Oncologists use immunotherapy at faster rates for trial-ineligible patients, study finds

Cancer patients who are ineligible for clinical trials receive immune checkpoint inhibitors (ICI) at greater rates than patients who are trial eligible despite no survival benefit, according to a new study by researchers at the Perelman School of Medicine at the University of Pennsylvania.

9 Nov 2021

Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

The immune checkpoint protein B7-H3 may be a promising new target for immunotherapy in treatment-resistant prostate cancers, according to two new studies led by researchers at the Johns Hopkins Kimmel Cancer Center.

2 Nov 2021

Researchers decipher when and why T cells become non-responsive to immunotherapy

Non-small cell lung cancer is the most common type of lung cancer in humans. Some patients with NSCLC receive a therapy called immune checkpoint blockade (ICB) that helps kill cancer cells by reinvigorating a subset of immune cells called T cells, which are "exhausted" and have stopped working.

30 Oct 2021

Daily use of cannabidiol oil may shrink lung tumors

It may be worth exploring further the use of cannabidiol ('CBD') oil as a potential lung cancer treatment, suggest doctors in BMJ Case Reports after dealing with a daily user whose lung tumor shrank without the aid of conventional treatment.

15 Oct 2021

Black NSCLC patients receiving immunotherapy have lower risk of death than white counterparts

Non-Hispanic Black patients with non-small cell lung cancer (NSCLC) who were treated with immunotherapy had a lower risk of death than their non-Hispanic white counterparts treated with immunotherapy, according to results presented at the virtual 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held October 6-8, 2021.

6 Oct 2021

Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

Osimertinib was the first drug to be approved for adjuvant treatment after complete tumour resection in adults with stage IB to IIIA non-small cell lung cancer (NSCLC).

2 Oct 2021

Researchers devise novel technique to count elusive circulating tumor cells

As tumors grow within an organ, they also release cells that enter the bloodstream. These cells can travel to other organs, seeding new tumors called metastases.

29 Sep 2021

Study findings could lead to novel ways to overcome tumor resistance to immunotherapies

Cancer-fighting immune cells in patients with lung cancer whose tumors do not respond to immunotherapies appear to be running on a different "program" that makes them less effective than immune cells in patients whose cancers respond to these immune treatments, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy.

22 Sep 2021

Oxford COVID vaccine technology has the potential to revolutionize cancer treatment

Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the success of the Oxford-AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer.

21 Sep 2021

Study uncovers a new way to counter immune suppression in tumors

Malignant tumors can enhance their ability to survive and spread by suppressing antitumor immune cells in their vicinity, but a study led by researchers at Weill Cornell Medicine and NewYork-Presbyterian has uncovered a new way to counter this immunosuppressive effect.

20 Sep 2021

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

New findings from a large study led by researchers at Yale Cancer Center shows the addition of the drugs oleclumab or monalizumab to durvalumab improved progression-free survival for patients with locally advanced non-small cell lung cancer (NSCLC).

18 Sep 2021

Study highlights the importance of deeply exploring the immune responses against cancer

Over the past decade, scientists have been exploring vaccination as a way to help fight cancer. These experimental cancer vaccines are designed to stimulate the body's own immune system to destroy a tumor, by injecting fragments of cancer proteins found on the tumor.

16 Sep 2021

Grouping EGFR mutations provides an accurate way to match lung cancer patients to the right drugs

Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations by structure and function provide an accurate framework to match patients with non-small cell lung cancer (NSCLC) to the right drugs.

16 Sep 2021

Lung cancer patients report high anxiety levels and experience treatment delays due to the pandemic

Patients coping with lung cancer and treated in one hospital in Mexico reported high levels of anxiety and saw their treatment delayed or due to the COVID-19 pandemic, according to a study presented today at the IASLC World Conference on Lung Cancer.

12 Sep 2021

Study shows how oncology practices changed after durvalumab approval for unresectable stage III NSCLC patients

A study presented today at the IASLC 2021 World Conference on Lung Cancer suggests how oncology practices in the United States changed after 2018, when durvalumab became available for patients with unresectable Stage III non-small cell lung cancer.

12 Sep 2021

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Treatment with atezolizumab plus carboplatin and pemetrexed was safe and yielded promising brain progression-free survival in patients with nonsquamous non-small cell lung cancer with untreated and asymptomatic brain metastases.

12 Sep 2021

Cellular program could turn T cells into effective cancer killers

9 Sep 2021

New insights could help unlock the mystery of how lung cancer arises in never smokers

A genomic analysis of lung cancer in people with no history of smoking has found that a majority of these tumors arise from the accumulation of mutations caused by natural processes in the body.

6 Sep 2021

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

A combination of metformin and chemoradiation in patients with locally advanced non-small cell lung cancer (LA-NSCLC) was not found to add survival benefit in the NRG Oncology clinical trial NRG-LU001. These results were recently published in JAMA Oncology.

25 Aug 2021

Non Small Cell Lung Cancer News and Research

Researchers develop model for early prediction of cancer patients' response to immunotherapy

Oncologists use immunotherapy at faster rates for trial-ineligible patients, study finds

Immune checkpoint protein may be a promising new target for prostate cancer immunotherapy

Researchers decipher when and why T cells become non-responsive to immunotherapy

Daily use of cannabidiol oil may shrink lung tumors

Black NSCLC patients receiving immunotherapy have lower risk of death than white counterparts

Osimertinib offers a hint of added benefit for NSCLC patients who have received adjuvant chemotherapy

Researchers devise novel technique to count elusive circulating tumor cells

Study findings could lead to novel ways to overcome tumor resistance to immunotherapies

Oxford COVID vaccine technology has the potential to revolutionize cancer treatment

Study uncovers a new way to counter immune suppression in tumors

Novel drug combinations improve progression-free survival for patients with advanced NSCLC

Study highlights the importance of deeply exploring the immune responses against cancer

Grouping EGFR mutations provides an accurate way to match lung cancer patients to the right drugs

Lung cancer patients report high anxiety levels and experience treatment delays due to the pandemic

Study shows how oncology practices changed after durvalumab approval for unresectable stage III NSCLC patients

Combination of chemotherapy and immune checkpoint inhibitors shows promise in NSCLC patients with untreated brain metastases

Cellular program could turn T cells into effective cancer killers

New insights could help unlock the mystery of how lung cancer arises in never smokers

Combination of metformin and chemoradiation does not add survival benefit in patients with LA-NSCLC

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News